These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12034846)

  • 1. Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progression.
    Stewart DA; Xu X; Thomas SD; Miller DM
    Nucleic Acids Res; 2002 Jun; 30(11):2565-74. PubMed ID: 12034846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoralen-modified clamp-forming antisense oligonucleotides reduce cellular c-Myc protein expression and B16-F0 proliferation.
    Stewart DA; Thomas SD; Mayfield CA; Miller DM
    Nucleic Acids Res; 2001 Oct; 29(19):4052-61. PubMed ID: 11574688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and and in mice.
    Leonetti C; D'Agnano I; Lozupone F; Valentini A; Geiser T; Zon G; Calabretta B; Citro G C; Zupi G
    J Natl Cancer Inst; 1996 Apr; 88(7):419-29. PubMed ID: 8618233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin.
    Leonetti C; Biroccio A; Candiloro A; Citro G; Fornari C; Mottolese M; Del Bufalo D; Zupi G
    Clin Cancer Res; 1999 Sep; 5(9):2588-95. PubMed ID: 10499637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice.
    Citro G; D'Agnano I; Leonetti C; Perini R; Bucci B; Zon G; Calabretta B; Zupi G
    Cancer Res; 1998 Jan; 58(2):283-9. PubMed ID: 9443406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells.
    Broaddus WC; Chen ZJ; Prabhu SS; Loudon WG; Gillies GT; Phillips LL; Fillmore H
    Neurosurgery; 1997 Oct; 41(4):908-15. PubMed ID: 9316053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence.
    Zupi G; Scarsella M; Semple SC; Mottolese M; Natali PG; Leonetti C
    Clin Cancer Res; 2005 Mar; 11(5):1990-8. PubMed ID: 15756025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth inhibition of SK-MEL-30 human melanoma cells by antisense c-myc oligonucleotides delivered by poly(N-isopropylacrylamide)/ poly(ethyleneimine) copolymer.
    Dinçer S; Oskay EK; Piskin AK; Zeybek ND; Pişkin E
    J Tissue Eng Regen Med; 2010 Jun; 4(4):284-90. PubMed ID: 19967748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
    Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
    Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration.
    Biro S; Fu YM; Yu ZX; Epstein SE
    Proc Natl Acad Sci U S A; 1993 Jan; 90(2):654-8. PubMed ID: 8421701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of cellular functions in retroorbital fibroblasts using antisense oligonucleotides targeting the c-myc protooncogene.
    Heufelder AE; Bahn RS
    Invest Ophthalmol Vis Sci; 1995 Jun; 36(7):1420-32. PubMed ID: 7775120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line.
    Leonetti C; Biroccio A; Benassi B; Stringaro A; Stoppacciaro A; Semple SC; Zupi G
    Cancer Gene Ther; 2001 Jun; 8(6):459-68. PubMed ID: 11498766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid-polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells.
    Ginobbi P; Geiser TA; Ombres D; Citro G
    Anticancer Res; 1997; 17(1A):29-35. PubMed ID: 9066627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
    Skorski T; Nieborowska-Skorska M; Wlodarski P; Zon G; Iozzo RV; Calabretta B
    Blood; 1996 Aug; 88(3):1005-12. PubMed ID: 8704208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft.
    Spugnini EP; Biroccio A; De Mori R; Scarsella M; D'Angelo C; Baldi A; Leonetti C
    J Transl Med; 2011 Jul; 9():125. PubMed ID: 21798045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of the sensitivity to cisplatin with c-myc over-expression or down-regulation in colon cancer cells.
    Funato T; Kozawa K; Kaku M; Sasaki T
    Anticancer Drugs; 2001 Nov; 12(10):829-34. PubMed ID: 11707650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of phosphodiester and phosphorothioate antisense oligodeoxynucleotides on cell lines which overexpress c-myc: implications for the treatment of Burkitt's lymphoma.
    Williams SA; Gillan ER; Knoppel E; Buzby JS; Suen Y; Cairo MS
    Ann Oncol; 1997; 8 Suppl 1():25-30. PubMed ID: 9187425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. c-myc antisense oligonucleotides sensitize human colorectal cancer cells to chemotherapeutic drugs.
    Abaza MS; Al-Saffar A; Al-Sawan S; Al-Attiyah R
    Tumour Biol; 2008; 29(5):287-303. PubMed ID: 18802399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination treatment of c-myc antisense DNA with all-trans-retinoic acid inhibits cell proliferation by downregulating c-myc expression in small cell lung cancer.
    Akie K; Dosaka-Akita H; Murakami A; Kawakami Y
    Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):243-9. PubMed ID: 10984118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
    Mizutani Y; Fukumoto M; Bonavida B; Yoshida O
    Cancer; 1994 Nov; 74(9):2546-54. PubMed ID: 7923012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.